JP7665337B2 - Ｅｐｓを媒介するための組成物および方法 - Google Patents

Ｅｐｓを媒介するための組成物および方法 Download PDF

Info

Publication number
JP7665337B2
JP7665337B2 JP2020571817A JP2020571817A JP7665337B2 JP 7665337 B2 JP7665337 B2 JP 7665337B2 JP 2020571817 A JP2020571817 A JP 2020571817A JP 2020571817 A JP2020571817 A JP 2020571817A JP 7665337 B2 JP7665337 B2 JP 7665337B2
Authority
JP
Japan
Prior art keywords
dna
agent
biofilm
antibody
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020571817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529180A5 (enExample
JP2021529180A (ja
Inventor
スティーブン デイビッド グッドマン，
ローレン オプレムカク バカレッツ，
Original Assignee
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル filed Critical リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Publication of JP2021529180A publication Critical patent/JP2021529180A/ja
Publication of JP2021529180A5 publication Critical patent/JP2021529180A5/ja
Priority to JP2024113962A priority Critical patent/JP2024138001A/ja
Application granted granted Critical
Publication of JP7665337B2 publication Critical patent/JP7665337B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020571817A 2018-06-29 2019-06-28 Ｅｐｓを媒介するための組成物および方法 Active JP7665337B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024113962A JP2024138001A (ja) 2018-06-29 2024-07-17 Ｅｐｓを媒介するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862692581P 2018-06-29 2018-06-29
US62/692,581 2018-06-29
PCT/US2019/040008 WO2020006528A2 (en) 2018-06-29 2019-06-28 Compositions and methods for mediating eps

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024113962A Division JP2024138001A (ja) 2018-06-29 2024-07-17 Ｅｐｓを媒介するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2021529180A JP2021529180A (ja) 2021-10-28
JP2021529180A5 JP2021529180A5 (enExample) 2022-06-28
JP7665337B2 true JP7665337B2 (ja) 2025-04-21

Family

ID=68985235

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571817A Active JP7665337B2 (ja) 2018-06-29 2019-06-28 Ｅｐｓを媒介するための組成物および方法
JP2024113962A Pending JP2024138001A (ja) 2018-06-29 2024-07-17 Ｅｐｓを媒介するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024113962A Pending JP2024138001A (ja) 2018-06-29 2024-07-17 Ｅｐｓを媒介するための組成物および方法

Country Status (12)

Country Link
US (1) US20210139610A1 (enExample)
EP (1) EP3813811A4 (enExample)
JP (2) JP7665337B2 (enExample)
KR (1) KR20210025075A (enExample)
CN (1) CN112672736A (enExample)
AU (2) AU2019291944B2 (enExample)
BR (1) BR112020026557A2 (enExample)
CA (1) CA3104140A1 (enExample)
IL (1) IL279459A (enExample)
MX (3) MX2020014006A (enExample)
SG (1) SG11202013060UA (enExample)
WO (1) WO2020006528A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170178A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
AU2019354829B2 (en) 2018-10-05 2025-04-17 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms
CA3183196A1 (en) * 2020-07-07 2022-01-13 Steven D. Goodman Combination therapies for the treatment and prevention of biofilms
US20220204600A1 (en) * 2020-12-30 2022-06-30 Trellis Bioscience, Inc. Therapeutic protein formulations comprising anti-dnabii antibodies and uses thereof
WO2022187274A1 (en) * 2021-03-01 2022-09-09 Carlo Ratti Combination therapy for treatment of conditions associated with aging
CN115304656B (zh) * 2022-06-22 2025-01-17 中国人民解放军海军军医大学第一附属医院 一种特异性激活细胞泛凋亡途径的囊泡药物构建及应用
CN118541144A (zh) * 2022-12-23 2024-08-23 中国医学科学院基础医学研究所 精胺在预防和治疗炎症性疾病中的用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526038A (ja) 2013-05-22 2016-09-01 カーザ グローバル エルエルシーＣｕｒｚａ Ｇｌｏｂａｌ， Ｌｌｃ ポリアミンを含む組成物及び方法
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
JP2017514887A (ja) 2014-03-13 2017-06-08 ザ セクレタリー オブ ステート フォー ヘルスＴｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｓｔａｔｅ Ｆｏｒ Ｈｅａｌｔｈ 抗菌性コンジュゲート、その製造方法及び使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100390332B1 (ko) * 2000-08-02 2003-07-07 유원민 항말라리아제와 항암제의 병용투여에 의한 항암제 복합 조성물
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
JP5670783B2 (ja) * 2011-03-07 2015-02-18 花王株式会社 バイオフィルムの除去方法
WO2012151555A1 (en) * 2011-05-04 2012-11-08 President And Fellows Of Harvard College Methods and coatings for treating biofilms
RU2694758C2 (ru) * 2012-12-20 2019-07-16 Раджив Бхушан Антимикробные композиции
EP2796876A1 (en) * 2013-04-25 2014-10-29 Hasenkam ApS Strip for monitoring analyte concentrations
US11013858B2 (en) * 2016-01-12 2021-05-25 David S. Goldsmith Nonjacketing side-entry connectors and prosthetic disorder response systems
US20150086561A1 (en) * 2013-09-26 2015-03-26 Trellis Bioscience, Llc Binding moieties for biofilm remediation
SG11201707345VA (en) * 2015-03-12 2017-10-30 Micreos Human Health Bv Combination of bactericidal agent with a lysosomotropic alkalinising agent for the treatment of a bacterial infection
US9801909B2 (en) * 2015-04-06 2017-10-31 The Penn State Research Foundation Compositions and methods for combating bacterial infections by killing persister cells with mitomycin C
FR3055801B1 (fr) * 2016-09-15 2020-10-30 Virbac Derives esters de squalamine pour le traitement des infections
CA3058813A1 (en) * 2017-04-05 2018-10-11 University Of Utah Research Foundation Compositions and methods comprising a triaryl polyamine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016526038A (ja) 2013-05-22 2016-09-01 カーザ グローバル エルエルシーＣｕｒｚａ Ｇｌｏｂａｌ， Ｌｌｃ ポリアミンを含む組成物及び方法
JP2017514887A (ja) 2014-03-13 2017-06-08 ザ セクレタリー オブ ステート フォー ヘルスＴｈｅ Ｓｅｃｒｅｔａｒｙ Ｏｆ Ｓｔａｔｅ Ｆｏｒ Ｈｅａｌｔｈ 抗菌性コンジュゲート、その製造方法及び使用
WO2017023863A1 (en) 2015-07-31 2017-02-09 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Agnieszka STACHURSKA et al.，"Cisplatin up-regulates the in vivo biosynthesis and degradation of renal polyamines and c-Myc expression"，Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease，2004年08月，Vol. 1689, No. 3，p.259-266，DOI: 10.1016/j.bbadis.2004.04.003
E． AGOSTINELLI et al.，"Polyamines: fundamental characters in chemistry and biology"，Amino Acids，2009年12月15日，Vol. 38、No. 2，p.393-403，DOI: 10.1007/s00726-009-0396-7
Enhancement of the antibiofilm activity of amphotericin B by polyamine biosynthesis inhibitors，InternationalJournal of Antimicrobial Agents，2015年，46(1)，45-52
F． FLAMIGNI et al.，"Polyamine biosynthesis as a target to inhibit apoptosis of non-tumoral cells"，Amino Acids，2007年06月20日，Vol. 33、No. 2，p.197-202，DOI: 10.1007/s00726-007-0514-3
Suzanne HECTOR et al.，"Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase"，Molecular Cancer Therapeutics，2004年07月01日，Vol. 3、No. 7，p.813-822，DOI: 10.1158/1535-7163.813.3.7
T MATTILA et al.，"Reversible inhibition of bacterial growth after specific inhibition of spermidine synthase by dicyclohexylamine"，Biochemical Journal，1984年11月01日，Vol. 223, No. 3，p.823-830，DOI: 10.1042/bj2230823
Veronica T. DUFE et al.，"A structural insight into the inhibition of human and Leishmania donovani ornithine decarboxylases by 1-amino-oxy-3-aminopropane"，Biochemical Journal，2007年06月27日，Vol. 405, No. 2，p.261-268，DOI: 10.1042/BJ20070188
YAKUGAKU ZASSHI，"Regulation of Polyamine and Cancer"，Keijiro SAMEJIMA，2006年08月01日，Vol. 126、No. 8，p.529-542，DOI: 10.1248/yakushi.126.529

Also Published As

Publication number Publication date
US20210139610A1 (en) 2021-05-13
MX2020014006A (es) 2021-05-27
KR20210025075A (ko) 2021-03-08
WO2020006528A3 (en) 2020-02-13
CN112672736A (zh) 2021-04-16
AU2019291944B2 (en) 2025-05-29
JP2021529180A (ja) 2021-10-28
MX2025008334A (es) 2025-08-01
SG11202013060UA (en) 2021-01-28
AU2019291944A1 (en) 2021-01-14
WO2020006528A2 (en) 2020-01-02
JP2024138001A (ja) 2024-10-07
IL279459A (en) 2021-01-31
EP3813811A2 (en) 2021-05-05
MX2025008333A (es) 2025-08-01
CA3104140A1 (en) 2020-01-02
EP3813811A4 (en) 2022-08-24
BR112020026557A2 (pt) 2021-04-06
AU2025208543A1 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
JP7665337B2 (ja) Ｅｐｓを媒介するための組成物および方法
US12239763B2 (en) Peptides and antibodies for the removal of biofilms
JP7627255B2 (ja) バイオフィルムを破壊するための抗体組成物
US12419944B2 (en) DNABII vaccines and antibodies with enhanced activity
US20160175440A1 (en) Compositions and methods for the treatment of burkholderia infections
US12098188B2 (en) Antibody fragments for the treatment of biofilm-related disorders
RU2851685C2 (ru) Композиции антител для разрушения биопленок
HK1255383B (en) Peptides and antibodies for the removal of biofilms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230731

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231230

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240327

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240717

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241023

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250313

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250326

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250409

R150 Certificate of patent or registration of utility model

Ref document number: 7665337

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150